Work package 3
In vitro and in vivo models of AD-related neuro-inflammation
In this work package 3 (WP3) in vivo experiments using animal models of Alzheimer’s disease (AD), human induced pluripotent stem cells (iPSC) and neuroimaging of patients to better understand neuroinflammatory responses in AD will be performed.
The first aim of WP3 is to use animal models of AD to understand the contribution of the activating/inhibiting innate immune receptors TREM2 and CD33 on disease progression and pathology.
The second aim of WP3 is to generate iPSCs with disease relevant genetic variants of TREM2 and CD33. A protocol for deriving human microglia/macrophages from iPSCs will be generated and the cells generated will be characterized to elucidate the function of the genetic risk genes TREM2 and CD33 for AD.
(image: A. Shahraz, UKB)
The third aim of WP3 is to perform neuroimaging and analysis of cerebrospinal fluid (CSF) of patients with/without TREM2/CD33 disease risk variants to understand the contribution of these genes to AD disease progression and pathology and find new biomarkers for AD.